AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer. June 17, 2016 05:44 AM Eastern Daylight Time. XIAMEN, China-- ...

TUCSON, Ariz., May 28, 2019 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, the first and only ...

CAMBRIDGE, England, October 2, 2012/ PRNewswire/--. Cytocell Ltd. today announced the availability of a new molecular cytogenetic test designed to identify the presence of gene rearrangements ...

Matthew Gubens, M.D., discussed the future of biomarker testing in non-small cell lung cancer. Experts are expecting a transformation in the process of testing for genetic mutations and molecular ...

The multitargeted tyrosine kinase inhibitor crizotinib is highly active in patients with lung cancer who harbor rearrangements in ALK 9,10 or ROS1. 11–13 Prompt identification of secondary ALK ...

AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer. June 17, 2016 05:44 AM Eastern Daylight Time. XIAMEN, China-- ...

- Roche's VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market - The biomarker may provide a cost ...

Cytocell Ltd. today announced the availability of a new molecular cytogenetic test designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung ...